DE69427469T2 - Kristallines ceftiofur (freie säure) - Google Patents

Kristallines ceftiofur (freie säure)

Info

Publication number
DE69427469T2
DE69427469T2 DE69427469T DE69427469T DE69427469T2 DE 69427469 T2 DE69427469 T2 DE 69427469T2 DE 69427469 T DE69427469 T DE 69427469T DE 69427469 T DE69427469 T DE 69427469T DE 69427469 T2 DE69427469 T2 DE 69427469T2
Authority
DE
Germany
Prior art keywords
crystalline
ceftiofur
free acid
oil
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69427469T
Other languages
German (de)
English (en)
Other versions
DE69427469D1 (en
Inventor
S. Bergren
S. Chao
J. Dunn
E. Hardee
L. Havens
Paul Shephard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69427469D1 publication Critical patent/DE69427469D1/de
Application granted granted Critical
Publication of DE69427469T2 publication Critical patent/DE69427469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69427469T 1993-03-12 1994-03-07 Kristallines ceftiofur (freie säure) Expired - Lifetime DE69427469T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3329193A 1993-03-12 1993-03-12
PCT/US1994/001862 WO1994020505A1 (en) 1993-03-12 1994-03-07 Crystalline ceftiofur free acid

Publications (2)

Publication Number Publication Date
DE69427469D1 DE69427469D1 (en) 2001-07-19
DE69427469T2 true DE69427469T2 (de) 2001-10-31

Family

ID=21869579

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69427469T Expired - Lifetime DE69427469T2 (de) 1993-03-12 1994-03-07 Kristallines ceftiofur (freie säure)
DE122005000055C Active DE122005000055I2 (de) 1993-03-12 1994-03-07 Kristallines ceftiofur (freie säure)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122005000055C Active DE122005000055I2 (de) 1993-03-12 1994-03-07 Kristallines ceftiofur (freie säure)

Country Status (31)

Country Link
US (1) US5721359A (show.php)
EP (1) EP0690864B1 (show.php)
JP (1) JP3852946B2 (show.php)
KR (1) KR100296810B1 (show.php)
CN (1) CN1055090C (show.php)
AT (1) ATE202109T1 (show.php)
AU (1) AU694419B2 (show.php)
BR (1) BR1101034A (show.php)
CA (1) CA2155322C (show.php)
CZ (1) CZ289332B6 (show.php)
DE (2) DE69427469T2 (show.php)
DK (1) DK0690864T3 (show.php)
ES (1) ES2157254T3 (show.php)
FI (1) FI120307B (show.php)
FR (1) FR05C0045I2 (show.php)
GR (1) GR3036514T3 (show.php)
HU (1) HU222244B1 (show.php)
IL (1) IL108910A (show.php)
LU (1) LU91206I2 (show.php)
LV (1) LV12889B (show.php)
NL (1) NL300208I2 (show.php)
NO (2) NO313199B1 (show.php)
NZ (1) NZ263002A (show.php)
PL (1) PL184611B1 (show.php)
PT (1) PT690864E (show.php)
RU (1) RU2136685C1 (show.php)
SI (1) SI0690864T1 (show.php)
SK (1) SK283674B6 (show.php)
TW (1) TW267170B (show.php)
WO (1) WO1994020505A1 (show.php)
ZA (1) ZA941586B (show.php)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
AU8832301A (en) * 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
BR0211061A (pt) * 2001-07-10 2004-07-20 Upjohn Co Cristais de tiazina oxazolidinonas e processos para isolar tais cristais
SI1419151T1 (sl) 2001-08-15 2014-04-30 Pharmacia & Upjohn Company Llc Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh
KR20040097187A (ko) 2002-03-21 2004-11-17 파마시아 앤드 업존 캄파니 동물의 귀로의 주사가능한 항생제의 투여 방법
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US20040115822A1 (en) * 2002-09-12 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US20040115837A1 (en) * 2002-11-27 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
MXPA05010083A (es) * 2003-03-27 2005-11-23 Basilea Pharmaceutica Ag Cefalosporina en forma cristalina.
US8039482B2 (en) * 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1934231A4 (en) * 2005-10-12 2011-10-26 Orchid Chemicals & Pharm Ltd CRYSTALLINE SODIUM SALT OF ANTIBIOTICS BASED ON CEPHALOSPORINE
US8470809B2 (en) * 2005-10-12 2013-06-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
US8431562B2 (en) * 2008-08-22 2013-04-30 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
MX2012009537A (es) * 2010-02-18 2012-08-31 Astrazeneca Ab Formas solidas que comprenden un derivado de ciclopropilamida.
AU2011218491C1 (en) * 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
MX2013012820A (es) 2011-05-02 2014-02-10 Zoetis Llc Cefalosporinas novedosas utiles como agentes antibacteriales.
KR20140063616A (ko) 2011-07-20 2014-05-27 브라이엄 영 유니버시티 소수성 세라게닌 화합물 및 이를 포함하는 기구
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
BR112014005914B1 (pt) 2011-09-13 2021-11-09 Brigham Young University Produtos para cicatrização de feridas tecidulares
EP2755661B1 (en) 2011-09-13 2026-08-05 Brigham Young University Compositions for treating bone diseases and broken bones
EP3449900A1 (en) 2011-12-21 2019-03-06 Brigham Young University Oral care compositions
CN102584855B (zh) * 2012-02-16 2014-06-25 青岛科技大学 一种改进的头孢噻呋的制备方法
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
CA2888259C (en) 2012-10-17 2019-05-28 Brigham Young University Treatment and prevention of mastitis
JP6310396B2 (ja) * 2012-12-03 2018-04-11 株式会社カネカ 還元型補酵素ｑ１０誘導体およびその製造方法
AU2014203882B2 (en) 2013-01-07 2016-06-23 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
BR112015023747B1 (pt) 2013-03-15 2023-04-18 Brigham Young University Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
RU2546675C2 (ru) * 2013-04-11 2015-04-10 Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП") Способ определения степени кристалличности составов на основе дифениламина
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
TWI637943B (zh) * 2013-09-05 2018-10-11 田邊三菱製藥股份有限公司 新穎結晶性芳烷基胺化合物及其製造方法
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
KR101753842B1 (ko) * 2015-05-12 2017-07-04 한국화학연구원 불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
CN106543203B (zh) * 2015-09-18 2019-07-02 瑞普（天津）生物药业有限公司 一种长效头孢噻呋自由酸晶体的制备方法
WO2017125557A1 (en) * 2016-01-22 2017-07-27 Sandoz Ag Crystalline eravacycline bis-hydrochloride
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
KR101898282B1 (ko) * 2016-05-24 2018-09-13 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
EA039753B1 (ru) * 2016-07-07 2022-03-10 Сайклерион Терапьютикс, Инк. ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US11186556B1 (en) * 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
UA119735C2 (uk) 2018-12-20 2019-07-25 Анатолій Семенович Редер Фармацевтична сполука, спосіб її отримання та застосування як лікарського засобу
ES3065954T3 (en) 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
TWI924727B (zh) * 2020-11-18 2026-05-11 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
CN117229296A (zh) * 2023-09-14 2023-12-15 广东温氏大华农生物科技有限公司 一种头孢噻呋酸晶体及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207933B (de) * 1962-12-26 1965-12-30 American Home Prod Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin
US3489750A (en) * 1967-09-05 1970-01-13 Bristol Myers Co 7-amino-cephalosporanic and decephalosporanic acid derivatives
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4400503A (en) * 1981-10-30 1983-08-23 Eli Lilly And Company Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid
DE3313818A1 (de) * 1983-04-16 1984-10-18 Hoechst Ag, 6230 Frankfurt Neue kristallmodifikation von ceftazidim
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IT1181672B (it) * 1984-10-25 1987-09-30 Upjohn Co Cefalosporina alogenidrato cristallino
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
DE3650526T2 (de) * 1985-08-12 1996-10-31 Upjohn Co Umwandlung des cephalosporin-hydrohalid-salzes zu einem alkalimetallsalz
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
IT1214587B (it) * 1986-12-23 1990-01-18 Giovanni Bonfanti Metodo per la produzione diprodotti cristallini puri.
DE3871542T2 (de) * 1987-02-02 1992-12-24 Lilly Co Eli Verfahren zur herstellung von ceftazidime-pentahydrat.
US5079007A (en) * 1987-07-29 1992-01-07 The Upjohn Company Controlled release of antibiotic salts from an implant
US5134137A (en) * 1987-11-10 1992-07-28 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes

Also Published As

Publication number Publication date
EP0690864A1 (en) 1996-01-10
LU91206I2 (fr) 2006-05-30
NO2005025I2 (no) 2010-11-22
BR1101034A (pt) 2002-04-30
CN1055090C (zh) 2000-08-02
HU222244B1 (hu) 2003-05-28
GR3036514T3 (en) 2001-12-31
RU2136685C1 (ru) 1999-09-10
DK0690864T3 (da) 2001-09-17
IL108910A0 (en) 1994-06-24
DE69427469D1 (en) 2001-07-19
PT690864E (pt) 2001-11-30
NL300208I2 (nl) 2006-05-01
ATE202109T1 (de) 2001-06-15
HU9501960D0 (en) 1995-09-28
NZ263002A (en) 1996-12-20
TW267170B (show.php) 1996-01-01
JPH08507519A (ja) 1996-08-13
ZA941586B (en) 1995-09-07
SI0690864T1 (en) 2001-10-31
CA2155322C (en) 2000-02-29
FI954250L (fi) 1995-09-11
FR05C0045I1 (show.php) 2006-01-06
FR05C0045I2 (show.php) 2007-08-03
ES2157254T3 (es) 2001-08-16
US5721359A (en) 1998-02-24
DE122005000055I1 (de) 2006-02-23
IL108910A (en) 1999-10-28
SK283674B6 (sk) 2003-11-04
JP3852946B2 (ja) 2006-12-06
LV12889B (lv) 2002-12-20
NO2005025I1 (no) 2005-12-05
NO953564D0 (no) 1995-09-11
AU694419B2 (en) 1998-07-23
PL310556A1 (en) 1995-12-27
CZ289332B6 (cs) 2002-01-16
NO313199B1 (no) 2002-08-26
CA2155322A1 (en) 1994-09-15
NL300208I1 (nl) 2006-02-01
FI120307B (fi) 2009-09-15
PL184611B1 (pl) 2002-11-29
DE122005000055I2 (de) 2008-06-05
EP0690864B1 (en) 2001-06-13
FI954250A0 (fi) 1995-09-11
NO953564L (no) 1995-11-07
KR100296810B1 (ko) 2001-10-24
CN1119016A (zh) 1996-03-20
AU6351094A (en) 1994-09-26
HUT73781A (en) 1996-09-30
SK111495A3 (en) 1995-12-06
CZ9502290A3 (cs) 2001-08-15
WO1994020505A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
US5721359A (en) Crystalline ceftiofur free acid
DE3143219C2 (show.php)
DE69814378T2 (de) Salz von naphthylidincarbonsäure-derivaten
DE60204897T2 (de) Kristalline freie base von clindamycin
DE3888913T2 (de) Kristallines beta-Lactam-Hydrat.
DE2738712C2 (show.php)
CH645118A5 (de) Cephalosporinantibiotikum.
DD284807A5 (de) Verf. z. herstellung eine pyhsikalischen gemisches aus mindestens einem salz des ((1-methyl-1-pyrrolidinio)- methyl)-3-cephem-4-carboxylats u. einer pharmazeutisch vertraeglichen, nicht toxischen, organischen oder anorganischen base
DE3037104C2 (de) Kristallines Bishydrochlorid von (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oximino)acetamido]-3-(1-pyridiniummethyl)ceph-3-em-4-carboxylat
DE60113243T2 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
JPS6145626B2 (show.php)
DE68922127T2 (de) Zinkceftiofurkomplexe.
DE3443065C2 (show.php)
DE3789264T2 (de) Beta-lactam-antibiotika.
DE3887691T2 (de) Cephalosporin-antibiotika.
DE60314920T2 (de) Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
DE2234280B2 (de) Cephalosporinverbindungen und Verfahren zu deren Herstellung
DE2522998A1 (de) Neues cephalosporinderivat, verfahren zu seiner herstellung und arzneimittel
DE68922207T2 (de) Verfahren zur Herstellung von Alkalimetall-Salze von 3,7-substituierten 7-Aminocephalosporansauerderivaten.
AT393452B (de) Verfahren zur herstellung eines cephalosporinpraeparates zur herstellung einer injektionsloesung
DE2622985B2 (de) Antibiotisches Mittel enthaltend 7- [D-a-Amino-a-(p-hydroxyphenyl) acetamido] -3-(t,2,3-triazol-5ylthiomethyl)-3- cephem-4-carbonsäure und Verfahren zu seiner Herstellung
DE3405172A1 (de) Erythromycinsalz der 2-(1,3-thiazolidin-3-yl)carbonylbenzoesaeure, verfahren zu seiner herstellung und es enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

SP81

Owner name: ZOETIS P&U LLC (N.D.GES.D. STAATES DELAWARE), FLORHAM PARK, NEW JERSEY 07932, US

Free format text: PREVIOUS APPLICANT: PHARMACIA & UPJOHN CO., KALAMAZOO, MICH., US; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Owner name: ZOETIS P&U LLC (N.D.GES.D. STAATES DELAWARE), FLORHAM PARK, US

Free format text: PREVIOUS APPLICANT: PHARMACIA & UPJOHN CO., KALAMAZOO, US; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

SP82

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE

Free format text: PREVIOUS REPRESENTATIVE: ; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

SP81

Owner name: ZOETIS SERVICES LLC, FLORHAM PARK, N.J., US

Free format text: PREVIOUS APPLICANT: ZOETIS P&U LLC (N.D.GES.D. STAATES DELAWARE), FLORHAM PARK, NEW JERSEY 07932, US; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

SP82

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE

R081 Change of applicant/patentee
R082 Change of representative
SP81

Owner name: ZOETIS SERVICES LLC (N.D.GES.D.STAATES DELAWARE), 07054 PARSIPPANY, N.J., US

Free format text: PREVIOUS APPLICANT: ZOETIS SERVICES LLC, FLORHAM PARK, N.J., US; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

SP82

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER, 80333 MUENCHEN, DE

Free format text: PREVIOUS REPRESENTATIVE: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE; PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055

Representative=s name: PATENTANWAELTE HENKEL, BREUER & PARTNER MBB, 80333 MUENCHEN, DE

R071 Expiry of right
SP71

Free format text: PRODUCT NAME: KRISTALLINE FORM DER FREIEN SAEURE VON CEFTIOFUR; AUTHORISATION NO/DATE: EU/2/05/053 20050519

Spc suppl protection certif: 122005000055